NCT04831112

Brief Summary

Honey is super saturated solution containing sugar derived from nectar gathered by honeybee. Honey is viscus supersaturated solution mainly composed of sugar and water along with minor constituents such as minerals, vitamins, amino acids, organic acids, flavonoids, and other phenolic compound and aromatic substances. Honey contents according to percentages are fructose 38.6%, glucose 31%, water 17%, lactose 7.2%, larger sugars 4.7% and rest of micronutrients and elemental compounds are 1.5%. Honey enhances wound healing by removing slough and necrotic tissue from wound. It promotes wound healing by increasing angiogenesis, granulation and epithelization. Honey possess antimicrobial activity against bacteria like methicillin resistant staphylococcus aureus, vancomycin resistant Escherichia Coli, pseudomonas aeruginosa, and many other species. It also has activity against some yeast species such as aspergillus and penicillium. Honey used for dressing will be 'Langnese Honey". Langnese honey is raw honey / unprocessed packed as collected, quality and quantity will be same for patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
326

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

March 21, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 5, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

November 15, 2022

Status Verified

November 1, 2022

Enrollment Period

1.8 years

First QC Date

March 21, 2021

Last Update Submit

November 13, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Early wound healing

    Early wound healing is measured via appearance of granulation tissue over the wound.

    3 weeks

Secondary Outcomes (1)

  • Decreased hospital stay

    4 weeks

Study Arms (2)

Honey

EXPERIMENTAL

Topical honey to be used for dressing 4ml per square inch.

Drug: HoneyCombination Product: EUSOL

EUSOL

ACTIVE COMPARATOR

EUSOL soaked gauze to be placed over the wound as dressing.

Drug: HoneyCombination Product: EUSOL

Interventions

HoneyDRUG

Dressing of necrotizing fascitis wounds with honey.

EUSOLHoney
EUSOLCOMBINATION_PRODUCT

Dressing of necrotizing fascitis wounds with EUSOL.

EUSOLHoney

Eligibility Criteria

Age18 Years - 70 Years
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years and \<70 years.
  • Necrotizing fasciitis wounds
  • Wide span of wound \<20cm

You may not qualify if:

  • Diabetic Foot wounds
  • Traumatic wounds

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr Ruth K.M Pfau Civil Hospital

Karachi, Sindh, 75000, Pakistan

Location

MeSH Terms

Conditions

Fasciitis, NecrotizingWound Infection

Interventions

HoneyEusol

Condition Hierarchy (Ancestors)

FasciitisMusculoskeletal DiseasesInfections

Intervention Hierarchy (Ancestors)

FoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Experimental randomised trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 21, 2021

First Posted

April 5, 2021

Study Start

March 1, 2020

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

November 15, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations